New and Emerging Targeted Therapies for Patients With DLBCL

In this podcast episode, Gilles Salles, MD, PhD, and Pier Luigi Zinzani, MD, PhD, discuss the role of new and emerging targeted therapies in the management of patients with DLBCL, including: Overview of Unmet Needs With Current Standard of Care in DLBCL Expanding Role of Novel Agents in DLBCL  Access to Targeted Therapies and Clinical Trials in Non-Academic DLBCL Practice  Key Ongoing Trials of new and novel agents in DLBCL  Key Presentations/Results at EHA 2026 in DLBCL Presenters:  Gilles Salles, MD, PhD Service Chief, Lymphoma Service Steven Greenberg Chair Memorial Sloan Kettering Cancer Center Weill Cornell University New York, New York Pier Luigi Zinzani, MD, PhD Professor of Hematology Alma Mater Studiorum-University of Bologna Head, “Seràgnoli” Institute of Hematology IRCCS Azienda Ospedaliero-Universitaria di Bologna Department of Medical and Surgical Sciences Bologna University School of Medicine Bologna, Italy Link to full program: https://bit.ly/4gmyoS7 Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.